Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models

Keyphrases

• Experimental Infection Model 100%
• Lantibiotics 100%
• Area under the Concentration Curve 100%
• Semi-synthetic 100%
• Antibacterial Activity 100%
• Methicillin-resistant S. Aureus 75%
• Staphylococcus Aureus 50%
• Lung 50%
• Vancomycin 50%
• Infection Model 50%
• Cross-resistance 25%
• Clinically Significant 25%
• Antibiotics 25%
• Protein Binding 25%
• Methicillin-resistant Staphylococcus Aureus 25%
• In Vitro Activity 25%
• Best Predictor 25%
• In Vivo Efficacy 25%
• Therapeutic Levels 25%
• Thigh Infection Model 25%
• Enterococcus Faecalis 25%
• Vancomycin-resistant Enterococci 25%
• Amide Coupling 25%
• Strong Resistance 25%
• In Vivo Activity 25%
• Mouse Plasma 25%
• Plasma Exposure 25%
• Lung Penetration 25%
• Vancomycin-intermediate S. Aureus 25%
• MIC Values 25%
• Gram-positive Infections 25%
• Disseminated Infection 25%
• Enterococcus Spp 25%
• Efficacy Predictor 25%
• Bronchoalveolar 25%
• Static Effect 25%
• Mouse Infection 25%
• Resistance Development 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Staphylococcus Aureus 100%
• Experimental Infection 100%
• Antibacterial Activity 100%
• Lantibiotic 100%
• Infection 66%
• Meticillin 50%
• Vancomycin 50%
• Cross-Resistance 16%
• Protein Binding 16%
• Infectious Agent 16%
• Antibiotics 16%
• Vancomycin-Resistant Enterococcus 16%
• Enterococcus faecalis 16%
• Carboxamide 16%
• Methicillin-Resistant Staphylococcus Aureus 16%
• Gram Positive Infection 16%

Immunology and Microbiology

• Staphylococcus Aureus 100%
• Antibacterial Activity 100%
• Lantibiotic 100%
• Blood Plasma 50%
• Minimum Inhibitory Concentration 50%
• Infectious Agent 16%
• Methicillin-Resistant Staphylococcus Aureus 16%
• Protein Binding 16%
• Carboxy Terminal Sequence 16%
• Enterococcus faecalis 16%
• Cross-Resistance 16%
• Vancomycin-Resistant Enterococcus 16%